TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33836974

Group type: EXPERIMENTAL
Intervention: Palbociclib (150 mg on days 5 to 18) and T-DM1 (day 1 intravenous) in 21-day treatment cycles
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Palbociclib and T-DM1
Number of subjects: 18
Study: 32384914

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo (with rescue with ketamine)
Number of subjects: 542
Study: 35609204

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 21
Study: 34000088

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7487

Group type: COMPARATOR
Intervention: Conventional dual-antiplatelet therapy (DAPT)
Number of subjects: 7487

Group type: EXPERIMENTAL
Intervention: GRACE risk score 2.0
Number of subjects: 7487
Study: 36093646

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV) with tidal volume adjusted to a target plateau pressure (Pplat ≤ 20 cm H2O) and PEEP (9 cm H2O)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional ventilation (CV) (8 ml/kg‐1VT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 61
Study: 32927478

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Co-infusion of Exendin 9-39 (Ex 9-39) (900 pmol/kg/min) with GLP-1
Number of subjects: 6

Group type: COMPARATOR
Intervention: GLP-1 infusion alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Co-infusion of Ex 9-39
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion and Ex 9-39
Number of subjects: 6
Study: 32452928

Group type: EXPERIMENTAL
Intervention: Targeted muscle reinnervation
Number of subjects: 33
Study: 33357070

Group type: EXPERIMENTAL
Intervention: Taurine (50 mg·kg‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 11
Study: 33610734

Group type: EXPERIMENTAL
Intervention: zolbetuximab + EOX (800 mg/m2 loading dose, then 600 mg/m2 Q3W)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: zolbetuximab + EOX (1000 mg/m2 Q3W)
Number of subjects: 246

Group type: COMPARATOR
Intervention: EOX alone
Number of subjects: 246
Study: 33884942

Group type: EXPERIMENTAL
Intervention: Cardiac Computed Tomography (CCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCT
Number of subjects: 0
Study: 32503507

Group type: EXPERIMENTAL
Intervention: Discussing LUTS with personal relations
Number of subjects: 4885

Group type: EXPERIMENTAL
Intervention: Having an available social network
Number of subjects: 4885

Group type: COMPARATOR
Intervention: Not discussing symptoms with personal or professional relations
Number of subjects: 4885
Study: 631083998

Group type: EXPERIMENTAL
Intervention: AR-paretic arm training (40 minutes/day, three days/week for four weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AR-paretic arm training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Regular therapy (during the four-week control period)
Number of subjects: 19
Study: 36333727

Group type: EXPERIMENTAL
Intervention: Coach McLungsSM intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 21
Study: 32658018

Group type: EXPERIMENTAL
Intervention: Femoral spike distance ratio
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Femoral spike distance >2 times the femoral radius
Number of subjects: 22

Group type: COMPARATOR
Intervention: Femoral spike area ratio
Number of subjects: 22
Study: 32120445

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion administered immediately after incision of the visceral peritoneum (Group I)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (Oxytocin infusion administered immediately after clamping the umbilical cord, Group II)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (Group I)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 101
Study: 35911242

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32122153

Group type: EXPERIMENTAL
Intervention: PleuraFlow® 32 F chest tube with FlowGlide™ active clearance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Argyle® 32 F chest tube
Number of subjects: 100
Study: 34496448

Group type: COMPARATOR
Intervention: 0 mg/kg esketamine (SK0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg esketamine (SK0.25)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg esketamine (SK0.5)
Number of subjects: 90
Study: 33556518

Group type: EXPERIMENTAL
Intervention: NPO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clear liquids
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (regular diet)
Number of subjects: 90
Study: 32408905

Group type: EXPERIMENTAL
Intervention: Anthracycline-free chemotherapy regimen (6x docetaxel/cyclophosphamide, TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anthracycline-taxane sequence (4xEC followed by 4x docetaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by endocrine therapy
Number of subjects: 0
Study: 35631240

Group type: EXPERIMENTAL
Intervention: Eufortyn® Colesterolo Plus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34444645

Group type: EXPERIMENTAL
Intervention: Protein‐rich nutritional composition supplementation (PS)
Number of subjects: 100
Study: 34776172

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Strength Exercise A (SEA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Strength Exercise B (SEB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (PRE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Strength Exercises (SEA and SEB)
Number of subjects: 12
Study: 32339775

Group type: EXPERIMENTAL
Intervention: FS4 coding strategy
Number of subjects: 34

Group type: COMPARATOR
Intervention: FSP coding strategy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FS4 and FSP coding strategies
Number of subjects: 34
Study: 35692883

Group type: EXPERIMENTAL
Intervention: Calcitriol combined with zoledronic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 60
Study: 33771846

Group type: EXPERIMENTAL
Intervention: Choice (self-collection at home for HPV testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care screening (cytology and HPV co-testing at Health Department clinics)
Number of subjects: 0
Study: 36069743

Group type: EXPERIMENTAL
Intervention: Online psychoeducational support group (6 sessions, 35-45 minutes each, via WhatsApp)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 33063950

Group type: EXPERIMENTAL
Intervention: Mother's vocalizations and gaze to partner's face and objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants' vocalizations timed with gaze to partner's face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyadic coordination of vocalizations and gaze
Number of subjects: 0
Study: 35400202

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP 110-139 mm Hg)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: High-to-low SBP group (from >210 mm Hg to <140 mm Hg)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: High-to-low SBP group
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Moderate SBP group
Number of subjects: 1000

Group type: COMPARATOR
Intervention: High SBP group
Number of subjects: 1000
Study: 34637343

Group type: EXPERIMENTAL
Intervention: PRC-063 (all doses combined)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: PRC-063 (45 mg)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: PRC-063 (70 mg)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: PRC-063 (C3SR Inattention)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: PRC-063 (CGI-I responders)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: PRC-063 (open-label treatment)
Number of subjects: 354
Study: 32149858

Group type: EXPERIMENTAL
Intervention: Full multiparametric CAD
Number of subjects: 4783

Group type: EXPERIMENTAL
Intervention: Abbreviated-protocol CAD
Number of subjects: 4783

Group type: COMPARATOR
Intervention: BI-RADS 3 and 4 lesions
Number of subjects: 4783
Study: 36333773

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) plus metformin
Number of subjects: 88
Study: 34024185

Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) scarf osteotomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Open scarf osteotomy
Number of subjects: 58
Study: 32299380

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: High-definition white-light endoscopy (HD-WLE)
Number of subjects: 41
Study: 35192050

Group type: EXPERIMENTAL
Intervention: RückenSPEZIAL (interdisciplinary second opinion procedure)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: RückenSPEZIAL with ISOP and IMPT
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: RückenSPEZIAL with solely ISOP without IMPT
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 216
Study: 33421630

Group type: EXPERIMENTAL
Intervention: Intervention group (patients with atrial fibrillation)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (patients without atrial fibrillation)
Number of subjects: 398
Study: 32060651

Group type: EXPERIMENTAL
Intervention: Dimercaptopropane Sulfonate (DMPS) + Dimercaptosuccinic Acid (DMSA) (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: D-penicillamine (DPA) (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study: 35347375

Group type: EXPERIMENTAL
Intervention: Isolated MPFL reconstruction (MPFL-R)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Active rehabilitation (Control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (MPFL-R and Control)
Number of subjects: 61
Study: 32013825

Group type: EXPERIMENTAL
Intervention: Chair multimodal exercise (CME, n=20; 80±8.19)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chair elastic band muscle‐strength exercise (CSE, n=21; 81±4.79)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control non‐exercise (CGne, n=19; 80±10.01)
Number of subjects: 60
Study: 35076832

Group type: EXPERIMENTAL
Intervention: Parent–Child Interaction Therapy (PCIT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study: 35660972

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and chemotherapy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mesothelioma risk score (MRS) based on high SII and low haemoglobin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: EORTC score
Number of subjects: 144
Study: 35044477

Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy/hysteropexy (SCP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Uphold Lite vaginal mesh
Number of subjects: 42
Study: 33386288

Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy with planning based on prostate-specific membrane antigen positron emission tomography/computed tomography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salvage radiation therapy without planning based on prostate-specific membrane antigen positron emission tomography/computed tomography
Number of subjects: 0
Study: 33047625

Group type: EXPERIMENTAL
Intervention: Exercise and computerized cognitive training (EX/CCT)
Number of subjects: 69
Study: 32419678

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion (0.2 mg/kg and 0.5 mg/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 71
Study: 33121063

Group type: EXPERIMENTAL
Intervention: PleurX catheter
Number of subjects: 13

Group type: COMPARATOR
Intervention: LVP
Number of subjects: 13
Study: 34560136

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 33421321

Group type: EXPERIMENTAL
Intervention: Off-label bevacizumab (q6w)
Number of subjects: 4536

Group type: COMPARATOR
Intervention: Licensed aflibercept (q8w)
Number of subjects: 4536
Study: 32673830

Group type: EXPERIMENTAL
Intervention: Accelerated antibiotic treatment (2 to 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard‐length antibiotic treatment (4 to 6 weeks)
Number of subjects: 0
Study: 34029682

Group type: EXPERIMENTAL
Intervention: Oral ferric maltol at 30mg twice daily for 16 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Oral ferric maltol at 30mg twice daily (continued treatment)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Switching from placebo to ferric maltol
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Ferric maltol
Number of subjects: 167
Study: 35120149

Group type: EXPERIMENTAL
Intervention: Neural mobilisation techniques and soft tissue mobilisation techniques for 30 minutes per session, 10 weekly sessions, plus advice to stay active on their activities of daily living, information on physical activity, imaging tests, and sciatica for 5 biweekly sessions lasting 25‐30 minutes.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Advice to stay active only.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Neural mobilisation techniques and soft tissue mobilisation techniques plus advice to stay active.
Number of subjects: 210
Study: 33583120

Group type: EXPERIMENTAL
Intervention: q2m belatacept
Number of subjects: 166

Group type: COMPARATOR
Intervention: q1m belatacept
Number of subjects: 166
Study: 32887558

Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (SYV) intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC)
Number of subjects: 128
Study: 35256034

Group type: EXPERIMENTAL
Intervention: Home-visiting intervention during pregnancy
Number of subjects: 32
Study: 33962320

Group type: EXPERIMENTAL
Intervention: Straight-sided glasses (A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual, predominantly curved glasses (B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of A and B
Number of subjects: 24
Study: 32520870

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking (low dose: 33.6 kJ·kg body weight per week)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking (moderate dose: 58.8 kJ·kg body weight per week)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking (moderate dose)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking (low dose)
Number of subjects: 61
Study: 36444207

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 mg intracanalicular insert (DEX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical prednisolone acetate (PRED)
Number of subjects: 20
Study: 32808022

Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paraxanthine
Number of subjects: 0
Study: 34852928

Group type: EXPERIMENTAL
Intervention: Patient-maintained propofol TCI sedation (PMPS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anaesthetist-controlled propofol TCI sedation (ACPS)
Number of subjects: 80
Study: 32634360

Group type: EXPERIMENTAL
Intervention: Earned Income Tax Credit of up to $2,000 (treatment)
Number of subjects: 5968

Group type: COMPARATOR
Intervention: Standard Earned Income Tax Credit of about $500 (control)
Number of subjects: 5968
Study: 34519136

Group type: EXPERIMENTAL
Intervention: Aspirin, paracetamol, and caffeine (APC)
Number of subjects: 3306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3306
Study: 33886430

Group type: COMPARATOR
Intervention: Trigger-based vaccination (TRV)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: SO plus vaccination started randomly on Days 11–35 of the response (VACr)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: SO plus vaccination with a fixed start on Day 21 of the response (VACf)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: SO only
Number of subjects: 6000
Study: 32773545

Group type: EXPERIMENTAL
Intervention: Resisted sled-pull training (light, moderate, heavy)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Heavy resisted sled-pull training
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Moderate to heavy resisted sled-pull training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unresisted sprinting
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All resisted groups
Number of subjects: 53
Study: 35778834

Group type: EXPERIMENTAL
Intervention: BT‐001 digital therapeutic (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control app
Number of subjects: 0
Study: 32828687

Group type: COMPARATOR
Intervention: Heat application group (HAG)
Number of subjects: 90
Study: 35977775

Group type: EXPERIMENTAL
Intervention: Watch Me Grow Integrated (WMG-I) approach for developmental screening
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Surveillance as Usual (SaU)
Number of subjects: 2000
Study: 34349369

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (Group U)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional palpatory method (Group P)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 36220461

Group type: EXPERIMENTAL
Intervention: CRT-TEM
Number of subjects: 173

Group type: COMPARATOR
Intervention: TME
Number of subjects: 173
Study: 32598093

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant treatment
Number of subjects: 763

Group type: COMPARATOR
Intervention: Nonusers of antidepressants
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant treatment (late starters excluded)
Number of subjects: 763
Study: 32720628

Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 346
Study: 36501066

Group type: EXPERIMENTAL
Intervention: Citrulline 3 g
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Citrulline 6 g
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 33630662

Group type: EXPERIMENTAL
Intervention: Combined memory treatment (traditional episodic memory therapy + semantic memory-focused therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 25
Study: 35448469

Group type: COMPARATOR
Intervention: 10 g sucrose (S‐group)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 g whey protein + 10 g sucrose (W‐S‐group)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 g whey protein (W‐group)
Number of subjects: 11
Study: 34666419

Group type: EXPERIMENTAL
Intervention: RYGB + Exercise Training (ET)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RYGB + ET
Number of subjects: 80

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 80
Study: 35750249

Group type: EXPERIMENTAL
Intervention: Rifaximin SSD IR 40 mg once-nightly
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Lactulose plus rifaximin SSD IR 40 mg bid
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587

Group type: COMPARATOR
Intervention: Lactulose plus placebo
Number of subjects: 587
Study: 32893328

Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32345344

Group type: EXPERIMENTAL
Intervention: MiLES intervention (online toolbox for employers during RTW process)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care as usual from employer
Number of subjects: 90
Study: 33003227

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1916
Study: 34610541

Group type: EXPERIMENTAL
Intervention: Preoperative methylprednisolone (40 mg or 120 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 180
Study: 32272030

Group type: EXPERIMENTAL
Intervention: Guideline-based physical therapy plus dry needling
Number of subjects: 116

Group type: COMPARATOR
Intervention: Guideline-based physical therapy
Number of subjects: 116
Study: 34157188

Group type: EXPERIMENTAL
Intervention: Elemental diet therapy (EDT) using an amino acid‐based formula
Number of subjects: 4
Study: 35544051

Group type: EXPERIMENTAL
Intervention: Microneedle array (MNA-25%) - 0.63 µg per patch, administered twice, 3 weeks apart
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Microneedle array (MNA-10%) - 0.25 µg per patch, administered twice, 3 weeks apart
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subcutaneous injection - 2.5 µg per injection, administered twice, 3 weeks apart
Number of subjects: 39
Study: 34578973

Group type: EXPERIMENTAL
Intervention: Caloric restriction with n-3 PUFA supplementation (1.8 g/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Caloric restriction without n-3 PUFA supplementation (placebo)
Number of subjects: 64
Study: 33079196

Group type: EXPERIMENTAL
Intervention: 0.4 mg/g VLNC cigarettes
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: 2.4 mg/g VLNC cigarettes
Number of subjects: 775

Group type: COMPARATOR
Intervention: 15.8 mg/g control cigarettes
Number of subjects: 775
Study: 34479188

Group type: EXPERIMENTAL
Intervention: Intraoperative halo-femoral traction (IOHFT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (nontraction) group
Number of subjects: 29
Study: 33713235

Group type: EXPERIMENTAL
Intervention: Low-dose ozone therapy
Number of subjects: 0
Study: 34981361

Group type: EXPERIMENTAL
Intervention: Empathic communication
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Shared decision-making
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Decision Support Analysis Tool (DSAT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Empathic Communication Coding System (ECCS)
Number of subjects: 30